These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

671 related items for PubMed ID: 15995948

  • 1. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations.
    Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, Upton A, Hindle Z, Fidler C, Kutzko D, Holdridge R, Lapointe C, Hamlet S, Chatfield SN.
    J Infect Dis; 2005 Aug 01; 192(3):360-6. PubMed ID: 15995948
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.
    Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C, Taylor DN.
    Vaccine; 2006 Jan 12; 24(2):116-23. PubMed ID: 16140433
    [Abstract] [Full Text] [Related]

  • 3. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units.
    Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, Larsson CJ, Martinez T, Feller A, Ventrone CH, Sack DA, DeNearing B, Fingar A, Pierce K, Dill EA, Schwartz HI, Beardsworth EE, Kilonzo B, May JP, Lam W, Upton A, Budhram R, Kirkpatrick BD.
    Vaccine; 2010 Apr 30; 28(20):3602-8. PubMed ID: 20188175
    [Abstract] [Full Text] [Related]

  • 4. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children.
    Tran TH, Nguyen TD, Nguyen TT, Ninh TT, Tran NB, Nguyen VM, Tran TT, Cao TT, Pham VM, Nguyen TC, Tran TD, Pham VT, To SD, Campbell JI, Stockwell E, Schultsz C, Simmons CP, Glover C, Lam W, Marques F, May JP, Upton A, Budhram R, Dougan G, Farrar J, Nguyen VV, Dolecek C.
    PLoS One; 2010 Jul 26; 5(7):e11778. PubMed ID: 20668668
    [Abstract] [Full Text] [Related]

  • 5. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA.
    Frey SE, Lottenbach KR, Hill H, Blevins TP, Yu Y, Zhang Y, Brenneman KE, Kelly-Aehle SM, McDonald C, Jansen A, Curtiss R.
    Vaccine; 2013 Oct 01; 31(42):4874-80. PubMed ID: 23916987
    [Abstract] [Full Text] [Related]

  • 6. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.
    Darton TC, Jones C, Blohmke CJ, Waddington CS, Zhou L, Peters A, Haworth K, Sie R, Green CA, Jeppesen CA, Moore M, Thompson BA, John T, Kingsley RA, Yu LM, Voysey M, Hindle Z, Lockhart S, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ.
    PLoS Negl Trop Dis; 2016 Aug 01; 10(8):e0004926. PubMed ID: 27533046
    [Abstract] [Full Text] [Related]

  • 7. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM.
    J Infect Dis; 2004 Aug 01; 190(3):565-70. PubMed ID: 15243933
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the antibodies in lymphocyte supernatant and antibody-secreting cell assays for measuring intestinal mucosal immune response to a novel oral typhoid vaccine (M01ZH09).
    Kirkpatrick BD, Bentley MD, Thern AM, Larsson CJ, Ventrone C, Sreenivasan MV, Bourgeois L.
    Clin Diagn Lab Immunol; 2005 Sep 01; 12(9):1127-9. PubMed ID: 16148184
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of phoP and rpoS mutants of Salmonella enterica serovar Typhi as attenuated typhoid vaccine candidates: virulence and protective immune responses in intranasally immunized mice.
    Lee HY, Cho SA, Lee IS, Park JH, Seok SH, Baek MW, Kim DJ, Lee SH, Hur SJ, Ban SJ, Lee YK, Han YK, Cho YK, Park JH.
    FEMS Immunol Med Microbiol; 2007 Nov 01; 51(2):310-8. PubMed ID: 17725620
    [Abstract] [Full Text] [Related]

  • 10. Induction of cellular immune response and anti-Salmonella enterica serovar typhi bactericidal antibodies in healthy volunteers by immunization with a vaccine candidate against typhoid fever.
    Salazar-González RM, Maldonado-Bernal C, Ramírez-Cruz NE, Rios-Sarabia N, Beltrán-Nava J, Castañón-González J, Castillo-Torres N, Palma-Aguirre JA, Carrera-Camargo M, López-Macías C, Isibasi A.
    Immunol Lett; 2004 May 15; 93(2-3):115-22. PubMed ID: 15158606
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity of Ty21a attenuated "Salmonella typhi" given with sodium bicarbonate or in enteric-coated capsules.
    Black R, Levine MM, Young C, Rooney J, Levine S, Clements ML, O'Donnell S, Hugues T, Germanier R.
    Dev Biol Stand; 1983 May 15; 53():9-14. PubMed ID: 6307787
    [Abstract] [Full Text] [Related]

  • 12. M-01ZH09, an oral live attenuated Salmonella enterica serovar Typhi vaccine for the prevention of typhoid fever.
    Jain SK.
    Curr Opin Mol Ther; 2009 Oct 15; 11(5):565-71. PubMed ID: 19806505
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, Khan RM, Marhaba R, Ali N, Malubay N, Kawade A, Saul A, Martin LB, Podda A.
    Lancet Infect Dis; 2014 Feb 15; 14(2):119-29. PubMed ID: 24290843
    [Abstract] [Full Text] [Related]

  • 14. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH, Kantele JM, Savolainen LE, Rombo L, Kantele A.
    Vaccine; 2015 Jan 09; 33(3):451-8. PubMed ID: 25433216
    [Abstract] [Full Text] [Related]

  • 15. Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella?
    Kantele A, Pakkanen SH, Siitonen A, Karttunen R, Kantele JM.
    Vaccine; 2012 Nov 26; 30(50):7238-45. PubMed ID: 23084770
    [Abstract] [Full Text] [Related]

  • 16. A preliminary report on the immunological responses after oral vaccine (Ty 21a).
    Sirianni MC, Turbessi G, Scarpati B, Russo G, Mascellino MT, Aiuti F.
    Boll Ist Sieroter Milan; 1984 Sep 26; 63(4):352-6. PubMed ID: 6394032
    [Abstract] [Full Text] [Related]

  • 17. Concomitant induction of CD4+ and CD8+ T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA.
    Salerno-Gonçalves R, Wyant TL, Pasetti MF, Fernandez-Viña M, Tacket CO, Levine MM, Sztein MB.
    J Immunol; 2003 Mar 01; 170(5):2734-41. PubMed ID: 12594304
    [Abstract] [Full Text] [Related]

  • 18. Antibody response to the protein antigens of "Salmonella typhi" during typhoid infection and following vaccination with a live oral typhoid vaccine Ty21a.
    Chau PY, Tsang RS.
    Dev Biol Stand; 1983 Mar 01; 53():29-31. PubMed ID: 6873471
    [Abstract] [Full Text] [Related]

  • 19. Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination.
    Pakkanen SH, Kantele JM, Kantele A.
    Vaccine; 2012 Sep 14; 30(42):6047-53. PubMed ID: 22858557
    [Abstract] [Full Text] [Related]

  • 20. Bacteremia associated with live attenuated chi8110 Salmonella enterica serovar Typhi ISP1820 in healthy adult volunteers.
    Frey SE, Bollen W, Sizemore D, Campbell M, Curtiss R.
    Clin Immunol; 2001 Oct 14; 101(1):32-7. PubMed ID: 11580224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.